QEL-005

PreclinicalSmall molecule

QEL-005 is one of 2 small molecule programs targeting Diffuse Cutaneous Systemic Sclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Cutaneous Systemic SclerosisRecruiting

Diffuse Cutaneous Systemic SclerosisPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Diffuse Cutaneous Systemic Sclerosis

#DrugCompanyPhaseTrials

Ianalumab

Novartis

Phase 2

1 2

QEL-005

QQuell Therapeutics Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Diffuse Cutaneous Systemic Sclerosis

NCT07473154

Clinical

Trials by Indication[1]

Diffuse Cutaneous Systemic Sclerosis1 trial

Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).

Recruiting·QQuell Therapeutics Limited·Preclinical·NCT07473154·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for QEL-005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QEL-005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QEL-005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Quell Therapeutics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: QQuell Therapeutics Limited

QEL-005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Diffuse Cutaneous Systemic Sclerosis1 trial

References

Drug Info

Quick Facts

Related News